What are the health risks of supraphysiologic testosterone concentrations in transgender men?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Health Risks of Supraphysiologic Testosterone in Transgender Men

Supraphysiologic testosterone doses in transgender men significantly increase the risk of erythrocytosis/polycythemia, cardiovascular events including thrombosis, and adverse metabolic changes—risks that are largely avoidable by maintaining testosterone levels within the normal physiological male range (350-700 ng/dL). 1

Primary Risks of Excessive Testosterone Dosing

The Endocrine Society explicitly warns that the risk of cross-sex hormone therapy arises from and is worsened by inadvertent or intentional use of supraphysiological doses 1. The key adverse outcomes include:

Hematologic Complications

  • Erythrocytosis/Polycythemia: The most consistently documented risk, with hemoglobin increases of 4.9-12.5% and hematocrit increases of 4.4-17.6% reported 2
  • Thrombotic events: A documented case of branch retinal artery occlusion occurred in a 45-year-old transgender man self-administering 250mg weekly testosterone enanthate (supraphysiologic dosing), who developed hemoglobin of 19.3 g/dL and hematocrit of 62% 3
  • This represents a hypercoagulable state that can lead to arterial and venous thrombosis 4

Cardiovascular Risks

Cardiovascular events are disproportionately represented in adverse event reports for transgender men on testosterone 5:

  • Pulmonary embolism occurred in 50% of reported cardiovascular cases
  • Median time to onset was 34 months
  • Notably, these events occurred in men aged 21-40 years—younger than typical cardiovascular risk populations 5

Mechanistic cardiovascular changes include 6:

  • Increased leukocyte-endothelium interactions
  • Elevated adhesion molecules (VCAM-1, E-selectin)
  • Increased proinflammatory cytokines (IL-6, TNF-alpha)
  • Reduced HDL cholesterol and increased atherogenic index

Metabolic Derangements

Over 10 years of testosterone therapy, even at physiologic dosing, transgender men experience 7:

  • Worsening lipid profiles: LDL, total cholesterol, and triglycerides increase; HDL decreases throughout treatment
  • Increased BMI (1.3-11.4%), waist circumference, and shift to android fat distribution
  • Increased metabolic syndrome prevalence by female criteria
  • However, fasting glucose and blood pressure showed minimal changes 7

Hepatic Effects

  • Up to 15% of transgender men on testosterone develop transient liver enzyme elevations 1
  • Serious hepatic toxicity is rare with parenteral or transdermal formulations (oral 17-alkylated testosterone is not recommended) 1

Critical Monitoring to Prevent Supraphysiologic Complications

The Endocrine Society guideline provides specific testosterone target ranges and monitoring schedules 1:

Testosterone Level Targets

  • Target range: 350-700 ng/dL (normal physiological male range)
  • For testosterone enanthate/cypionate injections: measure midway between injections
  • Adjust dose if levels are >700 ng/dL or <350 ng/dL

Monitoring Schedule

  • Complete blood count: Every 3 months for the first year, then 1-2 times yearly 1
  • Liver function tests: Same schedule as CBC
  • Lipids, fasting glucose, hemoglobin A1c (if diabetic): At regular visits
  • Weight and blood pressure: At every visit

Important Caveat

During the first 3-9 months of treatment, total testosterone levels may appear high while free testosterone levels are normal due to elevated SHBG in some biological females 1. This is a transient phenomenon and should not be mistaken for true supraphysiologic dosing.

Evidence Quality and Cardiovascular Mortality

A critical limitation exists in the evidence base: A systematic review found data were insufficient (very low quality evidence) to meaningfully assess death, stroke, myocardial infarction, or venous thromboembolism in transgender men 1. Long-term Dutch cohort studies found no increased cardiovascular mortality, but these studies had limitations 1.

More recent data show 34 cardiovascular deaths among 7,837 transgender men (1.81 per 1,000 person-years), though certainty of evidence remains low to very low 8. A 10-year cohort study recorded no major cardiovascular events but noted one case of atrial fibrillation 7.

Clinical Pitfalls to Avoid

  1. Self-administration of supraphysiologic doses: The case of retinal artery occlusion demonstrates the danger of unregulated testosterone use at 250mg weekly (far exceeding standard dosing) 3

  2. Inadequate monitoring: Failure to check CBC regularly can miss dangerous erythrocytosis before thrombotic complications occur

  3. Ignoring cardiovascular risk factors: Even young transgender men (21-40 years) can develop cardiovascular events, particularly with supraphysiologic dosing 5

  4. Misinterpreting early elevated total testosterone: Remember that SHBG elevation in the first 3-9 months can artificially elevate total testosterone while free testosterone remains normal 1

Risk Mitigation Strategy

Maintain testosterone in the physiological male range (350-700 ng/dL) through appropriate dosing and monitoring 1. When levels exceed this range:

  • Reduce testosterone dose immediately
  • Increase monitoring frequency for hematocrit (target <52%)
  • Assess for signs/symptoms of thrombosis
  • Evaluate cardiovascular risk factors and manage according to established guidelines 1

The evidence consistently shows that adverse outcomes are associated with supraphysiologic dosing, while physiologic testosterone replacement appears safer, though long-term cardiovascular data remain limited 1, 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.